Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III
Kit N Simpson, Annie N Simpson, Patrick D Mauldin, Yuko Y Palesch, Sharon D Yeatts, Dawn Kleindorfer, Thomas A Tomsick, Lydia D Foster, Andrew M Demchuk, Pooja Khatri, Michael D Hill, Edward C Jauch, Tudor G Jovin, Bernard Yan, Ruediger von Kummer, Carlos A Molina, Mayank Goyal, Wouter J Schonewille, Mikael Mazighi, Stefan T Engelter Show all
Journal of the American Heart Association | WILEY | Published : 2017
Awarded by NIH/NINDS
Awarded by Medical University of South Carolina through NIH-NCATS
Awarded by Alberta Innovates
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
This work was supported by NIH/NINDS grant numbers: UC U01NS052220, U01NS054630, and U01NS077304. Genentech Inc supplied study drug used for intra-arterial tPA in the Endovascular group. EKOS Corp, Concentric Inc, and Cordis Neurovascular, Inc supplied study catheters during Protocol Versions 1 to 3. In the United States, IMS III investigator meeting support was provided, in part, by Genentech Inc, EKOS Corp, and Concentric Inc. In Europe, IMS III investigator meeting support was provided, in part, by Boehringer Ingelheim. This publication was partially supported by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH-NCATS Grant Number UL1 TR001450. Data support for the study was provided through the CEDAR core funded by the MUSC Office of the Provost.